The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Randomized, Double-Blind, Placebo-Controlled, Crossover Study of Sertraline (Zoloft) for the Treatment of Hot Flashes in Women with Early Stage Breast Cancer Taking Tamoxifen
Abstract
We observed the relief of hot flashes in breast cancer survivors taking tamoxifen and treated with sertraline for depression. Our objective was to assess the effect of sertraline on the frequency and severity of hot flashes, mood status, and health-related quality of life. We used a randomized, double-blind, placebo-controlled, crossover study using 6 weeks of sertraline (50 mg each morning) versus placebo. Study participants were 62 breast cancer survivors from an oncology clinic in a tertiary care center on adjuvant tamoxifen reporting bothersome hot flashes. Patients were asked to keep a daily hot flash diary to record hot flash frequency and severity, from which hot flash scores (frequency x severity) were calculated. The Center for Epidemiologic Studies depression scale and Functional Assessment of Cancer Therapy--Breast (FACT-B) (at baseline, 6 weeks, and 12 weeks) were used to assess mood and quality of life. Sixty-two women were accrued. Forty-seven women (median age 53.9 years, range 36.6-77.1 years; 89% postmenopausal; 85.5% Caucasian) completed the first 6 weeks and 39 completed 12 weeks. The baseline daily hot flash frequency and score were 5.8 (standard deviation 4.1) and 11.5 (14.0), respectively. At the end of the first 6 weeks, hot flash frequency decreased by 50% in 36% of those taking sertraline compared to 27% taking placebo. In the crossover analysis, sertraline was significantly more effective than placebo: women crossing from placebo to sertraline had a decrease (-0.9 and -1.7) in hot flash frequency and score, whereas those crossing from sertraline to placebo had an increase (1.5 and 3.4) in hot flash frequency and score (p = 0.03 and 0.03). Forty-eight percent preferred the sertraline period, 11% preferred the placebo period, and 41% had no preference (p = 0.006). Measures of depression and quality of life were within normal range and did not change significantly within treatment groups. Sertraline decreases hot flashes in breast cancer survivors taking tamoxifen and women prefer sertraline to placebo. Further study of sertraline for the management of hot flashes is warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The functional assessment of cancer therapy scale: development and validation of the general measure
Cella, D. F., Tulsky, D. S., Gray, G., Sarafian, B., Linn, E., Bonomi, A., Silberman, M., Yellen, S. B., Winicour, P., & Brannon, J. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.3.570 · Cited by 6,020
Loprinzi, C. L., Kugler, J. W., Sloan, J. A., Mailliard, J. A., LaVasseur, B. I., Barton, D. L., Novotny, P. J., Dakhil, S. R., Rodger, K., Rummans, T. A., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03403-6 · Cited by 737
Megestrol acetate for the prevention of hot flashes.
Loprinzi, C. L., Michalak, J. C., Quella, S. K., O'Fallon, J. R., Hatfield, A. K., Nelimark, R. A., Dose, A. M., Fischer, T., Johnson, C., Klatt, N. E., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199408113310602 · Cited by 500
Stearns, V., Beebe, K. L., Iyengar, M., & Dube, E. (2003) · JAMA · doi:10.1001/jama.289.21.2827 · Cited by 496
Phase III Evaluation of Fluoxetine for Treatment of Hot Flashes
Loprinzi, C. L., Sloan, J. A., Perez, E. A., Quella, S. K., Stella, P. J., Mailliard, J. A., Halyard, M. Y., Pruthi, S., Novotny, P. J., & Rummans, T. A. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.6.1578 · Cited by 473
Freedman, R. R. (2001) · American Journal of Human Biology · doi:10.1002/ajhb.1077 · Cited by 369
Transdermal clonidine for ameliorating tamoxifen-induced hot flashes.
Goldberg, R. M., Loprinzi, C. L., O'Fallon, J. R., Veeder, M. H., Miser, A. W., Mailliard, J. A., Michalak, J. C., Dose, A. M., Rowland, K. M., & Burnham, N. L. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.1.155 · Cited by 292
Pilot evaluation of venlafaxine hydrochloride for the therapy of hot flashes in cancer survivors.
Loprinzi, C. L., Pisansky, T. M., Fonseca, R., Sloan, J. A., Zahasky, K. M., Quella, S. K., Novotny, P. J., Rummans, T. A., Dumesic, D. A., & Perez, E. A. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.7.2377 · Cited by 254
Stearns, V., Isaacs, C., Rowland, J., Crawford, J., Ellis, M. J., Kramer, R., Lawrence, W., Hanfelt, J. J., & Hayes, D. F. (2000) · Annals of Oncology · doi:10.1023/a:1008382706068 · Cited by 224
Risk of Breast Cancer According to Use of Antidepressants, Phenothizaines, and Anthistamines
Kelly, J. P., Rosenberg, L., Palmer, J. R., Rao, R. S., Strom, B. L., Stolley, P. D., Zauber, A. G., & Shapiro, S. (1999) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a010091 · Cited by 89
Cited by
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Nelson, H. D. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60346-3 · Cited by 729
Major depression after breast cancer: a review of epidemiology and treatment
Fann, J. R., Thomas-Rich, A. M., Katon, W. J., Cowley, D., Pepping, M., McGregor, B. A., & Gralow, J. (2008) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2007.10.008 · Cited by 586
The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen
Goetz, M. P., Knox, S. K., Suman, V. J., Rae, J. M., Safgren, S. L., Ames, M. M., Visscher, D. W., Reynolds, C., Couch, F. J., Lingle, W. L., et al. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9428-0 · Cited by 552
CYP2D6 and tamoxifen: DNA matters in breast cancer
Hoskins, J. M., Carey, L. A., & McLeod, H. L. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2683 · Cited by 322
Metadata
- Authors
- Kimmick, G. G., Lovato, J., McQuellon, R., Robinson, E., & Muss, H. B.
- Venue
- The Breast Journal
- Publisher
- Wiley
- Published
- 2006-03
- Volume
- 12
- Issue
- 2
- Pages
- 114-122
- ISSN
- 1075-122X (ISSN-L)
- 1524-4741
- OpenAlex
- W2058646840
- Cited by
- 160
- References
- 10
- FWCI
- 7.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Randomized, Double-Blind, Placebo-Controlled, Crossover Study of Sertraline (Zoloft) for the Treatment of Hot Flashes in Women with Early Stage Breast Cancer Taking Tamoxifen. https://app.cochat.ai/papers/10.1111/j.1075-122x.2006.00218.x
- The paper
- Kimmick, G. G., Lovato, J., McQuellon, R., Robinson, E., & Muss, H. B. (2006). Randomized, Double-Blind, Placebo-Controlled, Crossover Study of Sertraline (Zoloft) for the Treatment of Hot Flashes in Women with Early Stage Breast Cancer Taking Tamoxifen. The Breast Journal. https://doi.org/10.1111/j.1075-122x.2006.00218.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.